bluebird bio Inc. [NASDAQ: BLUE] gained 2.87% on the last trading session, reaching $63.84 price per share at the time. The company report on August 5, 2020 that bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress.
– First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206 – .
– Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketing Authorization Application (MAA) from EMA –.
bluebird bio Inc. represents 55.59 million in outstanding shares, while the company has a total market value of $4.26 billion with the latest information. BLUE stock price has been found in the range of $62.87 to $68.39.
If compared to the average trading volume of 1.25M shares, BLUE reached a trading volume of 1545655 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about bluebird bio Inc. [BLUE]:
RBC Capital Mkts have made an estimate for bluebird bio Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 13, 2020. The new note on the price target was released on March 27, 2020, representing the official price target for bluebird bio Inc. stock.
The Average True Range (ATR) for bluebird bio Inc. is set at 3.02, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 78.73. The Price to Book ratio for the last quarter was 3.17, with the Price to Cash per share for the same quarter was set at 13.65.
Trading performance analysis for BLUE stock
bluebird bio Inc. [BLUE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.16. With this latest performance, BLUE shares dropped by -3.77% in over the last four-week period, additionally sinking by -29.06% over the last 6 months – not to mention a drop of -47.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 49.61, with the RSI for the last a single of trading hit 51.90, and the three-weeks RSI is set at 50.95 for bluebird bio Inc. [BLUE]. The present Moving Average for the last 50 days of trading for this stock 64.07, while it was recorded at 62.36 for the last single week of trading, and 70.12 for the last 200 days.
bluebird bio Inc. [BLUE]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and bluebird bio Inc. [BLUE] shares currently have an operating margin of -1817.79 and a Gross Margin at +54.31. bluebird bio Inc.’s Net Margin is presently recorded at -1767.49.
Return on Total Capital for BLUE is now -46.20, given the latest momentum, and Return on Invested Capital for the company is -45.20. Return on Equity for this stock declined to -49.82, with Return on Assets sitting at -39.78. When it comes to the capital structure of this company, bluebird bio Inc. [BLUE] has a Total Debt to Total Equity ratio set at 14.86. Additionally, BLUE Total Debt to Total Capital is recorded at 12.94, with Total Debt to Total Assets ending up at 11.06. Long-Term Debt to Equity for the company is recorded at 13.29, with the Long-Term Debt to Total Capital now at 11.57.
Reflecting on the efficiency of the workforce at the company, bluebird bio Inc. [BLUE] managed to generate an average of -$724,411 per employee. Receivables Turnover for the company is 4,702.53 with a Total Asset Turnover recorded at a value of 0.02.bluebird bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
bluebird bio Inc. [BLUE]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, bluebird bio Inc. posted -3.73/share EPS, while the average EPS was predicted by analysts to be reported at -3.52/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -6.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLUE.
An analysis of insider ownership at bluebird bio Inc. [BLUE]
There are presently around $3,781 million, or 91.80% of BLUE stock, in the hands of institutional investors. The top three institutional holders of BLUE stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 6,820,314, which is approximately -8.796% of the company’s market cap and around 0.50% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 6,812,412 shares of the stock with an approximate value of $434.9 million in BLUE stocks shares; and CAPITAL WORLD INVESTORS, currently with $277.12 million in BLUE stock with ownership of nearly -17.582% of the company’s market capitalization.
Positions in bluebird bio Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 138 institutional holders increased their position in bluebird bio Inc. [NASDAQ:BLUE] by around 6,605,166 shares. Additionally, 125 investors decreased positions by around 7,699,805 shares, while 43 investors held positions by with 44,919,835 shares. The mentioned changes placed institutional holdings at 59,224,806 shares, according to the latest SEC report filing. BLUE stock had 38 new institutional investments in for a total of 650,189 shares, while 53 institutional investors sold positions of 1,144,328 shares during the same period.